Home > Insider Trading > Filing (0000874015-24-000144)

Filing Details

Accession Number:: 0000874015-24-000144
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-05-07 16:55:46
Reporting Period:: 2024-05-03

Accepted Time:: 2024-05-07 16:55:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Ionis Pharmaceuticals Inc	IONS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1206369	Iii Joseph Klein	2855 Gazelle Court Carlsbad CA 92010		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-05-03	1,318	$42.57	4,682	No	4	S	Indirect	by Trust
Common Stock	Disposition	2024-05-03	682	$42.94	4,000	No	4	S	Indirect	by Trust
Common Stock	Disposition	2024-05-03	1,269	$42.59	2,731	No	4	S	Indirect	by Trust
Common Stock	Disposition	2024-05-03	731	$42.98	2,000	No	4	S	Indirect	by Trust
Common Stock	Disposition	2024-05-03	1,070	$42.55	930	No	4	S	Indirect	by Trust
Common Stock	Disposition	2024-05-03	930	$42.90	0	No	4	S	Indirect	by Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	by Trust
No	4	S	Indirect	by Trust
No	4	S	Indirect	by Trust
No	4	S	Indirect	by Trust
No	4	S	Indirect	by Trust
No	4	S	Indirect	by Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	16,346	Direct
Common Stock	100	Indirect	by Son

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.36 to $42.79 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.80 to $43.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.36 to $42.77 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4.
The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.